Quick Win By The Algorithm: SCMP Jumps On Talk of Takeover Interest

Quick Win By The Algorithm

On December 4th, 2017, I Know First issued a bullish 3 day forecast for Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP). The forecast showed a signal of 100.54 and a predictability of 0.14. In accordance with the forecast, SCMP’s stock returned 21.88% over this period, solidifying another quick win by the I Know First algorithm.

SCMP’s stock jumped big time on Thursday December 7th.  The shares surged due to a rumor that Sucampo Pharmaceuticals is reviewing their options including a sale of the business after the company received takeover interest.  The biopharmaceutical company could be attractive to large drug makers with an interest in gastroenterology.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company’s marketed product includes AMITIZA (lubiprostone), a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. Its product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis. The company is also developing VTS-270, which is in a pivotal Phase 2b/3 trial for the treatment of Niemann-Pick Disease Type C1. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland.

Top Small Cap Stocks

Current I Know First subscribers received this bullish SCMP forecast on December 4th, 2017. 


Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.